Literature DB >> 16551287

Extracorporeal strategies for the removal of middle molecules.

James F Winchester1, Patrick F Audia.   

Abstract

Uremic toxins with a molecular weight of less than 500 Da are classified as small nitrogenous waste products. They are highly water soluble, relatively homogeneous, and have no protein binding. Other uremic retention toxins differ significantly from the small nitrogenous metabolite class in molecular weight, heterogeneity, protein binding, and hydrophobicity. The European Uremic Toxin Work Group subdivided molecules into two categories: protein-bound solutes and middle molecules. Middle molecules were defined as toxins in the molecular weight range of 500-60,000 Da, which exceeds the molecular weight of 2000 Da defined in the original middle molecule hypothesis. Under this new proposed definition, most of these middle molecules are low molecular weight peptides and proteins (LMWPs). This concise review focuses on LMWPs. The metabolism of LMWPs is described, including molecular weight, physical conformation, and charge. Factors influencing dialytic removal of LMWPs such as membrane characteristics, protein-membrane interactions, and solute removal mechanisms, as well as strategies to enhance clearance of these compounds are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16551287     DOI: 10.1111/j.1525-139X.2006.00135.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  7 in total

Review 1.  Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.

Authors:  Xiaoliang Wang; Jiang Liu; Christopher A Drummond; Joseph I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2017-04-03       Impact factor: 6.902

2.  Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.

Authors:  Christopher Yanucil; Dominik Kentrup; Isaac Campos; Brian Czaya; Kylie Heitman; David Westbrook; Gunars Osis; Alexander Grabner; Adam R Wende; Julian Vallejo; Michael J Wacker; Jose Alberto Navarro-Garcia; Gema Ruiz-Hurtado; Fuming Zhang; Yuefan Song; Robert J Linhardt; Kenneth White; Michael S Kapiloff; Christian Faul
Journal:  Kidney Int       Date:  2022-05-02       Impact factor: 18.998

3.  Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure.

Authors:  Andrew M Siedlecki; Xiaohua Jin; Anthony J Muslin
Journal:  Kidney Int       Date:  2009-01-21       Impact factor: 10.612

Review 4.  The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.

Authors:  Alexander Grabner; Christian Faul
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

5.  Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients.

Authors:  R Krishnasamy; C M Hawley; M J Jardine; M A Roberts; Y J Cho; M G Wong; A Heath; C L Nelson; S Sen; P F Mount; E M Pascoe; D Darssan; L A Vergara; P A Paul-Brent; N D Toussaint; D W Johnson; C A Hutchison
Journal:  BMC Nephrol       Date:  2018-04-17       Impact factor: 2.388

6.  Effect of plasma sodium concentration on blood pressure regulators during hemodialysis: a randomized crossover study.

Authors:  Esmée M Ettema; Johanna Kuipers; Martijn van Faassen; Henk Groen; Arie M van Roon; Joop D Lefrandt; Ralf Westerhuis; Ido P Kema; Harry van Goor; Ron T Gansevoort; Carlo A J M Gaillard; Casper F M Franssen
Journal:  BMC Nephrol       Date:  2018-08-22       Impact factor: 2.388

7.  Association Between High-Sensitivity Cardiac Troponin T and Echocardiographic Parameters in Chronic Kidney Disease: Results From the KNOW-CKD Cohort Study.

Authors:  Eunjeong Kang; Hyunjin Ryu; Jayoun Kim; Joongyub Lee; Kyu-Beck Lee; Dong-Wan Chae; Su Ah Sung; Soo Wan Kim; Curie Ahn; Kook-Hwan Oh
Journal:  J Am Heart Assoc       Date:  2019-09-13       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.